Bio-Techne Q4 GAAP EPS -$0.11, adjusted EPS $0.53; organic revenue +3%; announces Exosome divestiture

BIO-TECHNE Corp

2025-FY EPS reported $0.46 revenue$1,219,635,000

GAAP EPS loss of $0.11 vs $0.25 profit a year ago; adjusted EPS $0.53 vs $0.49.
Q4 organic revenue up 3% (reported 4%) to $317.0M; full year organic +5% to $1.2B.
Protein Sciences segment organic growth 4% (reported 6%) in Q4.
Announced divestiture of Exosome Diagnostics business including ExoDx Prostate test.
Board declared $0.08/share quarterly dividend, payable Aug 29, record Aug 18.

item 2.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.